IBDEI3FE ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,57630,1,3,0)
 ;;=3^Insomnia,Unspec
 ;;^UTILITY(U,$J,358.3,57630,1,4,0)
 ;;=4^G47.00
 ;;^UTILITY(U,$J,358.3,57630,2)
 ;;=^332924
 ;;^UTILITY(U,$J,358.3,57631,0)
 ;;=Z91.410^^267^2886^9
 ;;^UTILITY(U,$J,358.3,57631,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57631,1,3,0)
 ;;=3^Personal Hx of Adult Physical & Sexual Abuse
 ;;^UTILITY(U,$J,358.3,57631,1,4,0)
 ;;=4^Z91.410
 ;;^UTILITY(U,$J,358.3,57631,2)
 ;;=^5063619
 ;;^UTILITY(U,$J,358.3,57632,0)
 ;;=B35.1^^267^2887^22
 ;;^UTILITY(U,$J,358.3,57632,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57632,1,3,0)
 ;;=3^Tinea Unguium
 ;;^UTILITY(U,$J,358.3,57632,1,4,0)
 ;;=4^B35.1
 ;;^UTILITY(U,$J,358.3,57632,2)
 ;;=^119748
 ;;^UTILITY(U,$J,358.3,57633,0)
 ;;=L03.90^^267^2887^3
 ;;^UTILITY(U,$J,358.3,57633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57633,1,3,0)
 ;;=3^Cellulitis,Unspec
 ;;^UTILITY(U,$J,358.3,57633,1,4,0)
 ;;=4^L03.90
 ;;^UTILITY(U,$J,358.3,57633,2)
 ;;=^5009067
 ;;^UTILITY(U,$J,358.3,57634,0)
 ;;=L03.91^^267^2887^6
 ;;^UTILITY(U,$J,358.3,57634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57634,1,3,0)
 ;;=3^Lymphangitis,Acute,Unspec
 ;;^UTILITY(U,$J,358.3,57634,1,4,0)
 ;;=4^L03.91
 ;;^UTILITY(U,$J,358.3,57634,2)
 ;;=^5009068
 ;;^UTILITY(U,$J,358.3,57635,0)
 ;;=L25.9^^267^2887^4
 ;;^UTILITY(U,$J,358.3,57635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57635,1,3,0)
 ;;=3^Contact Dermatitis,Unspec Cause
 ;;^UTILITY(U,$J,358.3,57635,1,4,0)
 ;;=4^L25.9
 ;;^UTILITY(U,$J,358.3,57635,2)
 ;;=^5133647
 ;;^UTILITY(U,$J,358.3,57636,0)
 ;;=L40.0^^267^2887^17
 ;;^UTILITY(U,$J,358.3,57636,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57636,1,3,0)
 ;;=3^Psoriasis Vulgaris
 ;;^UTILITY(U,$J,358.3,57636,1,4,0)
 ;;=4^L40.0
 ;;^UTILITY(U,$J,358.3,57636,2)
 ;;=^5009160
 ;;^UTILITY(U,$J,358.3,57637,0)
 ;;=L40.2^^267^2887^1
 ;;^UTILITY(U,$J,358.3,57637,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57637,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,57637,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,57637,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,57638,0)
 ;;=L40.3^^267^2887^20
 ;;^UTILITY(U,$J,358.3,57638,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57638,1,3,0)
 ;;=3^Pustulosis Palmaris et Plantaris
 ;;^UTILITY(U,$J,358.3,57638,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,57638,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,57639,0)
 ;;=L40.4^^267^2887^5
 ;;^UTILITY(U,$J,358.3,57639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57639,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,57639,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,57639,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,57640,0)
 ;;=L40.8^^267^2887^18
 ;;^UTILITY(U,$J,358.3,57640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57640,1,3,0)
 ;;=3^Psoriasis,Other
 ;;^UTILITY(U,$J,358.3,57640,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,57640,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,57641,0)
 ;;=L40.9^^267^2887^19
 ;;^UTILITY(U,$J,358.3,57641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57641,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,57641,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,57641,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,57642,0)
 ;;=L57.0^^267^2887^2
 ;;^UTILITY(U,$J,358.3,57642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57642,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,57642,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,57642,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,57643,0)
 ;;=L97.911^^267^2887^16
 ;;^UTILITY(U,$J,358.3,57643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,57643,1,3,0)
 ;;=3^Non-Prs Chr Ulc,Rt Low Leg,Limited to Brkdwn Skin
 ;;^UTILITY(U,$J,358.3,57643,1,4,0)
 ;;=4^L97.911
